Baidu
map

三功能双特异性抗体Catumaxomab治疗腹膜癌,获得NMPA授权开始全球性3期临床试验

2020-07-16 MedSci原创 MedSci原创

Catumaxomab是一种三功能双特异性抗体,该抗体结合肿瘤细胞上的跨膜糖蛋白-上皮细胞粘附分子(EpCAM)和T细胞上的CD3,还通过FcγR结合募集免疫辅助细胞。

凌腾医药(Lintonpharm)宣布,中国国家药品监督管理局(NMPA)授权该公司双特异性抗体卡妥索单抗(Catumaxomab)治疗腹膜癌患者的III期临床试验(NCT04222114)。腹膜癌是一种已扩散到腹腔中的晚期胃癌

Catumaxomab是2009年获得欧洲药品管理局(EMA)批准的首个T细胞结合双特异性抗体,用于治疗恶性腹水。恶性腹水是腹膜腔积液,表明存在恶性细胞。

LintonPharm的联合创始人兼首席科学官Horst Lindhofer博士说:“胃癌是全球第六大最常见的癌症。70%的患者位于中国,大多数患者诊断时为晚期。鉴于这一未得到满足的高度需求,我们希望catumaxomab将提供新的治疗选择。”

关于晚期胃癌伴腹膜癌

腹膜癌(PC)是晚期胃癌的主要死亡原因之一,PC胃癌的预后极差,预期生存期不到一年。胃癌的当前疗法包括Her2阳性患者使用曲妥珠单抗和全身化疗。对于一线治疗失败的患者,选择有限。

关于Catumaxomab

Catumaxomab是一种三功能双特异性抗体,该抗体结合肿瘤细胞上的跨膜糖蛋白-上皮细胞粘附分子(EpCAM)和T细胞上的CD3,还通过FcγR结合募集免疫辅助细胞。Catumaxomab通过T细胞和辅助细胞介导的细胞毒性杀死肿瘤细胞,并且由于独特的FcγR结合和激活特性,具有针对肿瘤细胞的长期疫苗潜力。

See the source image

图片来源:https://www.deutsche-apotheker-zeitung.de/daz-az/2009/daz-28-2009/catumaxomab-wirkt-gegen-krebsstammzellen

原始出处:

https://www.firstwordpharma.com/node/1740921?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1899403, encodeId=04ea18994036d, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Fri Jan 01 20:35:25 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912409, encodeId=a06719124092a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Aug 20 05:35:25 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911254, encodeId=262e191125459, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1289, encryptionId=18171289d6, topicName=3期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d275294, createdName=andy2087, createdTime=Sun Aug 30 20:35:25 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803543, encodeId=bb778035433a, content=腹膜癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/956eb01f4b594ee783debae7a44d9096/e569cb8381764328b493c23491d86c27.jpg, createdBy=2cbc5401622, createdName=老婆子, createdTime=Mon Jul 20 20:24:27 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025818, encodeId=d2c010258182c, content=双特异性抗体是热点,但是也不一定都有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Jul 19 11:35:25 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280096, encodeId=28531280096e2, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85660, encryptionId=94f28566004, topicName=腹膜癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526479, encodeId=437315264e91b, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595516, encodeId=86481595516a1, content=<a href='/topic/show?id=371912932d' target=_blank style='color:#2F92EE;'>#3期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1293, encryptionId=371912932d, topicName=3期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79cd18252620, createdName=slcumt, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623849, encodeId=a6ca162384955, content=<a href='/topic/show?id=16ba8564526' target=_blank style='color:#2F92EE;'>#腹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85645, encryptionId=16ba8564526, topicName=腹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e220615097, createdName=xuyong530, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803029, encodeId=d8e6803029be, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Jul 16 21:45:22 CST 2020, time=2020-07-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1899403, encodeId=04ea18994036d, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Fri Jan 01 20:35:25 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912409, encodeId=a06719124092a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Aug 20 05:35:25 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911254, encodeId=262e191125459, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1289, encryptionId=18171289d6, topicName=3期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d275294, createdName=andy2087, createdTime=Sun Aug 30 20:35:25 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803543, encodeId=bb778035433a, content=腹膜癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/956eb01f4b594ee783debae7a44d9096/e569cb8381764328b493c23491d86c27.jpg, createdBy=2cbc5401622, createdName=老婆子, createdTime=Mon Jul 20 20:24:27 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025818, encodeId=d2c010258182c, content=双特异性抗体是热点,但是也不一定都有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Jul 19 11:35:25 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280096, encodeId=28531280096e2, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85660, encryptionId=94f28566004, topicName=腹膜癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526479, encodeId=437315264e91b, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595516, encodeId=86481595516a1, content=<a href='/topic/show?id=371912932d' target=_blank style='color:#2F92EE;'>#3期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1293, encryptionId=371912932d, topicName=3期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79cd18252620, createdName=slcumt, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623849, encodeId=a6ca162384955, content=<a href='/topic/show?id=16ba8564526' target=_blank style='color:#2F92EE;'>#腹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85645, encryptionId=16ba8564526, topicName=腹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e220615097, createdName=xuyong530, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803029, encodeId=d8e6803029be, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Jul 16 21:45:22 CST 2020, time=2020-07-16, status=1, ipAttribution=)]
    2020-08-20 snf701207
  3. [GetPortalCommentsPageByObjectIdResponse(id=1899403, encodeId=04ea18994036d, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Fri Jan 01 20:35:25 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912409, encodeId=a06719124092a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Aug 20 05:35:25 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911254, encodeId=262e191125459, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1289, encryptionId=18171289d6, topicName=3期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d275294, createdName=andy2087, createdTime=Sun Aug 30 20:35:25 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803543, encodeId=bb778035433a, content=腹膜癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/956eb01f4b594ee783debae7a44d9096/e569cb8381764328b493c23491d86c27.jpg, createdBy=2cbc5401622, createdName=老婆子, createdTime=Mon Jul 20 20:24:27 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025818, encodeId=d2c010258182c, content=双特异性抗体是热点,但是也不一定都有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Jul 19 11:35:25 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280096, encodeId=28531280096e2, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85660, encryptionId=94f28566004, topicName=腹膜癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526479, encodeId=437315264e91b, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595516, encodeId=86481595516a1, content=<a href='/topic/show?id=371912932d' target=_blank style='color:#2F92EE;'>#3期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1293, encryptionId=371912932d, topicName=3期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79cd18252620, createdName=slcumt, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623849, encodeId=a6ca162384955, content=<a href='/topic/show?id=16ba8564526' target=_blank style='color:#2F92EE;'>#腹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85645, encryptionId=16ba8564526, topicName=腹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e220615097, createdName=xuyong530, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803029, encodeId=d8e6803029be, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Jul 16 21:45:22 CST 2020, time=2020-07-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1899403, encodeId=04ea18994036d, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Fri Jan 01 20:35:25 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912409, encodeId=a06719124092a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Aug 20 05:35:25 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911254, encodeId=262e191125459, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1289, encryptionId=18171289d6, topicName=3期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d275294, createdName=andy2087, createdTime=Sun Aug 30 20:35:25 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803543, encodeId=bb778035433a, content=腹膜癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/956eb01f4b594ee783debae7a44d9096/e569cb8381764328b493c23491d86c27.jpg, createdBy=2cbc5401622, createdName=老婆子, createdTime=Mon Jul 20 20:24:27 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025818, encodeId=d2c010258182c, content=双特异性抗体是热点,但是也不一定都有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Jul 19 11:35:25 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280096, encodeId=28531280096e2, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85660, encryptionId=94f28566004, topicName=腹膜癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526479, encodeId=437315264e91b, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595516, encodeId=86481595516a1, content=<a href='/topic/show?id=371912932d' target=_blank style='color:#2F92EE;'>#3期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1293, encryptionId=371912932d, topicName=3期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79cd18252620, createdName=slcumt, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623849, encodeId=a6ca162384955, content=<a href='/topic/show?id=16ba8564526' target=_blank style='color:#2F92EE;'>#腹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85645, encryptionId=16ba8564526, topicName=腹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e220615097, createdName=xuyong530, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803029, encodeId=d8e6803029be, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Jul 16 21:45:22 CST 2020, time=2020-07-16, status=1, ipAttribution=)]
    2020-07-20 老婆子

    腹膜癌

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1899403, encodeId=04ea18994036d, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Fri Jan 01 20:35:25 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912409, encodeId=a06719124092a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Aug 20 05:35:25 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911254, encodeId=262e191125459, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1289, encryptionId=18171289d6, topicName=3期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d275294, createdName=andy2087, createdTime=Sun Aug 30 20:35:25 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803543, encodeId=bb778035433a, content=腹膜癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/956eb01f4b594ee783debae7a44d9096/e569cb8381764328b493c23491d86c27.jpg, createdBy=2cbc5401622, createdName=老婆子, createdTime=Mon Jul 20 20:24:27 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025818, encodeId=d2c010258182c, content=双特异性抗体是热点,但是也不一定都有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Jul 19 11:35:25 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280096, encodeId=28531280096e2, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85660, encryptionId=94f28566004, topicName=腹膜癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526479, encodeId=437315264e91b, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595516, encodeId=86481595516a1, content=<a href='/topic/show?id=371912932d' target=_blank style='color:#2F92EE;'>#3期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1293, encryptionId=371912932d, topicName=3期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79cd18252620, createdName=slcumt, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623849, encodeId=a6ca162384955, content=<a href='/topic/show?id=16ba8564526' target=_blank style='color:#2F92EE;'>#腹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85645, encryptionId=16ba8564526, topicName=腹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e220615097, createdName=xuyong530, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803029, encodeId=d8e6803029be, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Jul 16 21:45:22 CST 2020, time=2020-07-16, status=1, ipAttribution=)]
    2020-07-19 研发小兵

    双特异性抗体是热点,但是也不一定都有效!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1899403, encodeId=04ea18994036d, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Fri Jan 01 20:35:25 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912409, encodeId=a06719124092a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Aug 20 05:35:25 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911254, encodeId=262e191125459, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1289, encryptionId=18171289d6, topicName=3期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d275294, createdName=andy2087, createdTime=Sun Aug 30 20:35:25 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803543, encodeId=bb778035433a, content=腹膜癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/956eb01f4b594ee783debae7a44d9096/e569cb8381764328b493c23491d86c27.jpg, createdBy=2cbc5401622, createdName=老婆子, createdTime=Mon Jul 20 20:24:27 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025818, encodeId=d2c010258182c, content=双特异性抗体是热点,但是也不一定都有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Jul 19 11:35:25 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280096, encodeId=28531280096e2, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85660, encryptionId=94f28566004, topicName=腹膜癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526479, encodeId=437315264e91b, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595516, encodeId=86481595516a1, content=<a href='/topic/show?id=371912932d' target=_blank style='color:#2F92EE;'>#3期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1293, encryptionId=371912932d, topicName=3期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79cd18252620, createdName=slcumt, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623849, encodeId=a6ca162384955, content=<a href='/topic/show?id=16ba8564526' target=_blank style='color:#2F92EE;'>#腹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85645, encryptionId=16ba8564526, topicName=腹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e220615097, createdName=xuyong530, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803029, encodeId=d8e6803029be, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Jul 16 21:45:22 CST 2020, time=2020-07-16, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1899403, encodeId=04ea18994036d, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Fri Jan 01 20:35:25 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912409, encodeId=a06719124092a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Aug 20 05:35:25 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911254, encodeId=262e191125459, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1289, encryptionId=18171289d6, topicName=3期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d275294, createdName=andy2087, createdTime=Sun Aug 30 20:35:25 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803543, encodeId=bb778035433a, content=腹膜癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/956eb01f4b594ee783debae7a44d9096/e569cb8381764328b493c23491d86c27.jpg, createdBy=2cbc5401622, createdName=老婆子, createdTime=Mon Jul 20 20:24:27 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025818, encodeId=d2c010258182c, content=双特异性抗体是热点,但是也不一定都有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Jul 19 11:35:25 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280096, encodeId=28531280096e2, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85660, encryptionId=94f28566004, topicName=腹膜癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526479, encodeId=437315264e91b, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595516, encodeId=86481595516a1, content=<a href='/topic/show?id=371912932d' target=_blank style='color:#2F92EE;'>#3期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1293, encryptionId=371912932d, topicName=3期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79cd18252620, createdName=slcumt, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623849, encodeId=a6ca162384955, content=<a href='/topic/show?id=16ba8564526' target=_blank style='color:#2F92EE;'>#腹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85645, encryptionId=16ba8564526, topicName=腹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e220615097, createdName=xuyong530, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803029, encodeId=d8e6803029be, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Jul 16 21:45:22 CST 2020, time=2020-07-16, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1899403, encodeId=04ea18994036d, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Fri Jan 01 20:35:25 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912409, encodeId=a06719124092a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Aug 20 05:35:25 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911254, encodeId=262e191125459, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1289, encryptionId=18171289d6, topicName=3期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d275294, createdName=andy2087, createdTime=Sun Aug 30 20:35:25 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803543, encodeId=bb778035433a, content=腹膜癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/956eb01f4b594ee783debae7a44d9096/e569cb8381764328b493c23491d86c27.jpg, createdBy=2cbc5401622, createdName=老婆子, createdTime=Mon Jul 20 20:24:27 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025818, encodeId=d2c010258182c, content=双特异性抗体是热点,但是也不一定都有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Jul 19 11:35:25 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280096, encodeId=28531280096e2, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85660, encryptionId=94f28566004, topicName=腹膜癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526479, encodeId=437315264e91b, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595516, encodeId=86481595516a1, content=<a href='/topic/show?id=371912932d' target=_blank style='color:#2F92EE;'>#3期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1293, encryptionId=371912932d, topicName=3期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79cd18252620, createdName=slcumt, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623849, encodeId=a6ca162384955, content=<a href='/topic/show?id=16ba8564526' target=_blank style='color:#2F92EE;'>#腹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85645, encryptionId=16ba8564526, topicName=腹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e220615097, createdName=xuyong530, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803029, encodeId=d8e6803029be, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Jul 16 21:45:22 CST 2020, time=2020-07-16, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1899403, encodeId=04ea18994036d, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Fri Jan 01 20:35:25 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912409, encodeId=a06719124092a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Aug 20 05:35:25 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911254, encodeId=262e191125459, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1289, encryptionId=18171289d6, topicName=3期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d275294, createdName=andy2087, createdTime=Sun Aug 30 20:35:25 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803543, encodeId=bb778035433a, content=腹膜癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/956eb01f4b594ee783debae7a44d9096/e569cb8381764328b493c23491d86c27.jpg, createdBy=2cbc5401622, createdName=老婆子, createdTime=Mon Jul 20 20:24:27 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025818, encodeId=d2c010258182c, content=双特异性抗体是热点,但是也不一定都有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Jul 19 11:35:25 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280096, encodeId=28531280096e2, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85660, encryptionId=94f28566004, topicName=腹膜癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526479, encodeId=437315264e91b, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595516, encodeId=86481595516a1, content=<a href='/topic/show?id=371912932d' target=_blank style='color:#2F92EE;'>#3期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1293, encryptionId=371912932d, topicName=3期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79cd18252620, createdName=slcumt, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623849, encodeId=a6ca162384955, content=<a href='/topic/show?id=16ba8564526' target=_blank style='color:#2F92EE;'>#腹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85645, encryptionId=16ba8564526, topicName=腹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e220615097, createdName=xuyong530, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803029, encodeId=d8e6803029be, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Jul 16 21:45:22 CST 2020, time=2020-07-16, status=1, ipAttribution=)]
    2020-07-18 xuyong530
  10. [GetPortalCommentsPageByObjectIdResponse(id=1899403, encodeId=04ea18994036d, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Fri Jan 01 20:35:25 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912409, encodeId=a06719124092a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Aug 20 05:35:25 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911254, encodeId=262e191125459, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1289, encryptionId=18171289d6, topicName=3期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d275294, createdName=andy2087, createdTime=Sun Aug 30 20:35:25 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803543, encodeId=bb778035433a, content=腹膜癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/956eb01f4b594ee783debae7a44d9096/e569cb8381764328b493c23491d86c27.jpg, createdBy=2cbc5401622, createdName=老婆子, createdTime=Mon Jul 20 20:24:27 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025818, encodeId=d2c010258182c, content=双特异性抗体是热点,但是也不一定都有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Jul 19 11:35:25 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280096, encodeId=28531280096e2, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85660, encryptionId=94f28566004, topicName=腹膜癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526479, encodeId=437315264e91b, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595516, encodeId=86481595516a1, content=<a href='/topic/show?id=371912932d' target=_blank style='color:#2F92EE;'>#3期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1293, encryptionId=371912932d, topicName=3期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79cd18252620, createdName=slcumt, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623849, encodeId=a6ca162384955, content=<a href='/topic/show?id=16ba8564526' target=_blank style='color:#2F92EE;'>#腹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85645, encryptionId=16ba8564526, topicName=腹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e220615097, createdName=xuyong530, createdTime=Sat Jul 18 02:35:25 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803029, encodeId=d8e6803029be, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Jul 16 21:45:22 CST 2020, time=2020-07-16, status=1, ipAttribution=)]
    2020-07-16 wxl882001

    了解一下

    0

相关资讯

Gynecol Oncol:遗传性妇科肿瘤基因测试全面述评(综述)

遗传性肿瘤综合征的特点包括家庭成员之间的多重影响,发病年龄早,存在多个和/或双边原发癌,虽然这些临床标记早已为人所知晓。目前或许可以识别一些会导致个体遗传乳腺癌、妇科和胃肠道癌症的基因突变。最近一项研究发现,24%未经筛选的卵巢癌存在生殖系突变,包括18%的BRCA1或BRCA2突变。 近日,美国H. Lee Moffitt癌症中心和研究所的Lancaster JM等对遗传性妇科肿瘤

2018 KSOG立场声明:双侧输卵管切除术降低平均风险女性卵巢癌/输卵管癌/腹膜癌风险

基于当前关于双侧输卵管切除术针对女性卵巢癌/输卵管癌/腹膜癌风险的预防作用的理解,KSGO联合多家韩国医学专业学会组织达成了相关共识。

英国NICE批准将PARP抑制剂Lynparza,用于BRCA1或BRCA2突变的铂敏感型卵巢癌、输卵管癌或腹膜癌复发患者

英国国立卫生研究院(NICE)已推荐将默沙东和阿斯利康的PARP抑制剂Lynparza(olaparib)片剂用于BRCA1或BRCA2突变的铂敏感型卵巢癌、输卵管癌或腹膜癌复发的成年人。

NICE批准PARP抑制剂Lynparza扩展用于晚期卵巢癌、输卵管癌和腹膜癌的维持治疗

MSD和阿斯利康的抗癌药Lynparza(olaparib)已获得英国国家健康与护理卓越研究所(NICE)的适应症扩展用于某些癌症的维持治疗。

Gynecol Oncol:含贝伐单抗方案在复发性低级别浆液性卵巢癌及腹膜癌中的应用

低级别浆液性卵巢癌(LGSOC)和腹膜癌(LGSPC)面临着独特的临床挑战。虽然这种病理类型仅占浆液性卵巢癌的10%,但它比其他高级别浆液癌有更高的耐药率。标准化的以铂类为基础的化疗对此病理类型效果稍差,这些都促使人们探索其他的治疗模式,包括更强调手术的重要性,更换化疗方案,靶向治疗等。 鉴于血管生成在肿瘤发生发展中的重要性,针对于VEGF(血管内皮生长因子)及其他血管生成路径的研究开展起来。贝

患者招募:评价SCB-313用于治疗腹膜癌患者的I期临床试验

腹膜肿瘤历来被肿瘤医生视为一大临床挑战。目前没有有效的治疗方法,仍然是全球范围内众多癌症患者高度未满足的临床急需。因此,期待评估SCB-313作为治疗腹膜肿瘤的潜在新疗法。

Baidu
map
Baidu
map
Baidu
map